Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03234738 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Safety and PK Study of IV TP-271
A Phase 1 study, sponsored by Tetraphase Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03234738 is a Phase 1 study that has completed, run by Tetraphase Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT03234738, a Phase 1 study, has completed, sponsored by Tetraphase Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a single-center, randomized, placebo-controlled, double-blind, multiple-ascending-dose, inpatient study to assess the safety, tolerability, and pharmacokinetics of TP-271 in healthy subjects. Subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this study.
Interventions
- DRUG Placebo
- DRUG TP-271
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-08-16 |
| Est. Completion | 2018-01-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03234738
The ClinicalTrials.gov registry entry for NCT03234738 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetraphase Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03234738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03234738 about?
NCT03234738 is a clinical study titled "A Phase 1 Safety and PK Study of IV TP-271". This is a single-center, randomized, placebo-controlled, double-blind, multiple-ascending-dose, inpatient study to assess the safety, tolerability, and pharmacokinetics of TP-271 in healthy subjects. Subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this s...
What is the current status of trial NCT03234738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2017-08-16. Estimated completion is 2018-01-02.
What interventions are being tested in trial NCT03234738?
The interventions under investigation include: Placebo (DRUG), TP-271 (DRUG).
Who is sponsoring clinical trial NCT03234738?
This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.